Beijing Tiantan Biological Products Corp Ltd Capital Reinvestment Ratio
Beijing Tiantan Biological Products Corp Ltd capital reinvestment ratio. Beijing Tiantan Biological Products Corp Ltd (600161) has a Capital Reinvestment Ratio of 0.39x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥318.80 Million) in capital expenditures (CN¥125.07 Million). See 600161 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Beijing Tiantan Biological Products Corp Ltd (1998–2024)
Capital reinvestment ratio of Beijing Tiantan Biological Products Corp Ltd from 1998 to 2024. This chart tracks Beijing Tiantan Biological Products Corp Ltd's Capital Reinvestment Ratio across 27 annual periods. See financial agility of Beijing Tiantan Biological Products Corp to measure the company's free cash flow as a share of total liabilities.
Beijing Tiantan Biological Products Corp Ltd Capital Reinvestment Ratio by Year (1998–2024)
Beijing Tiantan Biological Products Corp Ltd capital reinvestment ratio by year from 1998 to 2024. For the full cash flow conversion analysis, see 600161 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.30x | CN¥819.78 Million | CN¥1.07 Billion | ▲ +189.2% |
| 2023 | 0.45x | CN¥2.39 Billion | CN¥1.08 Billion | ▼ -62.6% |
| 2022 | 1.20x | CN¥1.13 Billion | CN¥1.35 Billion | ▲ +4.2% |
| 2021 | 1.15x | CN¥980.35 Million | CN¥1.13 Billion | ▲ +33.1% |
| 2020 | 0.87x | CN¥702.11 Million | CN¥608.91 Million | ▲ +5.9% |
| 2019 | 0.82x | CN¥642.47 Million | CN¥526.23 Million | ▲ +88.9% |
| 2018 | 0.43x | CN¥677.92 Million | CN¥293.90 Million | ▼ -34.6% |
| 2017 | 0.66x | CN¥218.39 Million | CN¥144.87 Million | ▲ +35.7% |
| 2016 | 0.49x | CN¥428.37 Million | CN¥209.39 Million | ▼ -23.0% |
| 2015 | 0.64x | CN¥473.26 Million | CN¥300.57 Million | ▼ -34.6% |
| 2014 | 0.97x | CN¥477.95 Million | CN¥464.16 Million | ▲ +0.3% |
| 2013 | 0.97x | CN¥566.43 Million | CN¥548.37 Million | ▼ -25.0% |
| 2012 | 1.29x | CN¥432.00 Million | CN¥557.87 Million | ▼ -36.5% |
| 2011 | 2.04x | CN¥353.15 Million | CN¥718.67 Million | ▲ +26.4% |
| 2010 | 1.61x | CN¥184.85 Million | CN¥297.54 Million | ▲ +277.4% |
| 2009 | 0.43x | CN¥448.23 Million | CN¥191.17 Million | ▼ -21.6% |
| 2008 | 0.54x | CN¥276.39 Million | CN¥150.31 Million | ▲ +25.8% |
| 2007 | 0.43x | CN¥153.55 Million | CN¥66.40 Million | ▼ -6.6% |
| 2006 | 0.46x | CN¥154.36 Million | CN¥71.50 Million | ▲ +53.3% |
| 2005 | 0.30x | CN¥131.69 Million | CN¥39.78 Million | ▼ -61.3% |
| 2004 | 0.78x | CN¥110.11 Million | CN¥85.89 Million | ▼ -45.5% |
| 2003 | 1.43x | CN¥62.93 Million | CN¥90.02 Million | ▲ +246.6% |
| 2002 | 0.41x | CN¥84.38 Million | CN¥34.83 Million | ▼ -60.9% |
| 2001 | 1.06x | CN¥46.49 Million | CN¥49.09 Million | ▲ +14.9% |
| 2000 | 0.92x | CN¥47.90 Million | CN¥44.04 Million | ▼ -9.7% |
| 1999 | 1.02x | CN¥42.58 Million | CN¥43.34 Million | ▼ -58.1% |
| 1998 | 2.43x | CN¥23.71 Million | CN¥57.61 Million | — |